Glucagon-like peptide-1 receptor agonists in patients with moyamoya disease and type 2 diabetes mellitus

Key Points

• To investigate the effects of GLP-1 receptor agonists on stroke risk and mortality in patients with moyamoya disease and type 2 diabetes mellitus.
• Analyzed clinical outcomes in patients with moyamoya disease and type 2 diabetes
• Assessed stroke, intracerebral hemorrhage, and death rates
• Examined treatment with GLP-1 receptor agonists
• Patients using GLP-1 receptor agonists had lower rates of stroke
• Incidence of intracerebral hemorrhage was reduced
• Mortality rates among these patients declined